Drug Trial Radar · NCT06057610
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
868
Actual
Start
Nov 1, 2023
Primary completion
Jul 15, 2026
Study completion Oct 2032
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of SHR-A1811 with or without pertuzumab versus trastuzumab, pertuzumab and docetaxel in HER2-Positive Recurrent or Metastatic Breast Cancer
Conditions
- HER2-PositiveRecurrent or Metastatic Breast Cancer
Interventions
SHR-A1811 InjectionDrug
SHR-A1811 Injection
SHR-A1811 Injection ; Pertuzumab InjectionDrug
SHR-A1811 Injection ; Pertuzumab Injection
Trastuzumab Injection;Pertuzumab Injection ; Docetaxel InjectionDrug
Trastuzumab Injection;Pertuzumab Injection ; Docetaxel Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival by Blinded Independent Central ReviewTime frame: from first dose to disease progression, or death, whichever comes first, up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.